Sartorius Stedim Biotech S.A. (ETR:56S1)
Germany · Delayed Price · Currency is EUR | Market Cap | 17.83B -10.6% |
| Revenue (ttm) | 2.98B +4.4% |
| Net Income | 268.10M +31.2% |
| EPS | 2.76 +30.7% |
| Shares Out | n/a |
| PE Ratio | 66.52 |
| Forward PE | 34.73 |
| Dividend | 0.69 (0.40%) |
| Ex-Dividend Date | Mar 31, 2026 |
| Volume | 48 |
| Open | 178.80 |
| Previous Close | 177.60 |
| Day's Range | 178.80 - 179.60 |
| 52-Week Range | 151.50 - 223.50 |
| Beta | 1.15 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jul 23, 2026 |
About Sartorius Stedim Biotech
Sartorius Stedim Biotech S.A. engages in the production and sale of instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; reagents; advanced therapies; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transportation of intermediate and finished biological products. It also provides fluid management services; biolayer interferometry instruments; microbiolog... [Read more]
Financial Performance
In 2025, Sartorius Stedim Biotech's revenue was 2.97 billion, an increase of 6.74% compared to the previous year's 2.78 billion. Earnings were 265.60 million, an increase of 51.68%.
Financial StatementsNews
Sartorius Stedim Biotech Earnings Call Transcript: Q1 2026
Sales grew 7.5% in constant currencies in Q1 2026, with strong recurring business and resilient profitability. Full-year guidance is confirmed, expecting 5%-9% sales growth and EBITDA margin above 30%, while deleveraging and disciplined investment continue.
Sartorius Stedim Biotech Earnings release: Q1 2026
Sartorius Stedim Biotech released its Q1 2026 earnings on April 23, 2026, summarizing the period's financial results.
Sartorius Stedim Biotech Slides: Q1 2026
Sartorius Stedim Biotech has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on April 23, 2026.
Sartorius Stedim Biotech Transcript: AGM 2026
The meeting confirmed strong 2025 financial growth, approved all resolutions, and outlined strategic priorities in innovation, operational efficiency, and sustainability. Dividend of €0.71 per share was proposed, and auditors issued unqualified opinions. All agenda items passed with high shareholder participation.
Sartorius Stedim Biotech Slides: FY 2026
Sartorius Stedim Biotech has posted slides in relation to its FY 2026 quarterly earnings report, which was published on March 24, 2026.
Sartorius Stedim Biotech Transcript: CMD 2026
Ambitious midterm targets include 8%-11% organic revenue growth and margin expansion, driven by innovation in single-use technologies, AI, and advanced therapies. Regional growth is led by the U.S. and Asia, with operational excellence and customer experience as key priorities.
Sartorius Stedim Biotech Press release: FY 2026
Sartorius Stedim Biotech issued a press release on March 17, 2026, disclosing material business information to investors.
Sartorius Stedim Biotech Slides: FY 2026
Sartorius Stedim Biotech has posted slides in relation to its FY 2026 quarterly earnings report, which was published on March 17, 2026.
Sartorius Stedim Biotech Earnings Call Transcript: Q4 2025
Full-year results exceeded upgraded guidance, with strong recurring revenue growth and improved profitability. 2026 outlook anticipates 5%-9% sales growth and higher margins, supported by innovation, operational discipline, and a robust order book.
Sartorius Stedim Biotech Annual report: Q4 2025
Sartorius Stedim Biotech has published its Q4 2025 annual report on February 3, 2026.
Sartorius Stedim Biotech Earnings release: Q4 2025
Sartorius Stedim Biotech released its Q4 2025 earnings on February 3, 2026, summarizing the period's financial results.
Sartorius Stedim Biotech Slides: Q4 2025
Sartorius Stedim Biotech has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on February 3, 2026.
Sartorius Stedim Biotech Earnings Call Transcript: Q3 2025
Sales grew 7.5% in constant currencies to €2.6B, driven by strong consumables demand and margin expansion to 29.7%. BPS delivered double-digit growth, while LPS improved gradually. Full-year guidance was raised, with continued deleveraging and robust innovation pipeline.
Sartorius Stedim Biotech Earnings release: Q3 2025
Sartorius Stedim Biotech released its Q3 2025 earnings on October 16, 2025, summarizing the period's financial results.
Sartorius Stedim Biotech Slides: Q3 2025
Sartorius Stedim Biotech has posted slides in relation to its Q3 2025 quarterly earnings report, which was published on October 16, 2025.
Sartorius Stedim Biotech and Nanotein Technologies Partner to Advance Cell Therapy Manufacturing
AUBAGNE, France--(BUSINESS WIRE)-- #CGT--Sartorius Stedim Biotech and Nanotein Technologies Partner to Advance Cell Therapy Manufacturing.
Bio Usawa Biotechnology and Sartorius Stedim Biotech Forge Partnership to Pioneer Biopharmaceutical Manufacturing in Africa
KIGALI, Rwanda and SAN FRANCISCO and AUBAGNE, France, July 29, 2025 (GLOBE NEWSWIRE) -- Bio Usawa Biotechnology, Ltd. (Bio Usawa), a leading African biotechnology firm, and Sartorius Stedim Biotech, a...
Sartorius Stedim Biotech Earnings Call Transcript: Q2 2025
Revenue grew 6% in constant currencies in H1 2025, led by strong consumables demand and margin expansion. BPS delivered robust growth, while LPS faced ongoing challenges. Full-year guidance is confirmed, with continued focus on deleveraging and innovation.
Sartorius Stedim Biotech Earnings release: Q2 2025
Sartorius Stedim Biotech released its Q2 2025 earnings on July 22, 2025, summarizing the period's financial results.
Sartorius Stedim Biotech Quarterly report: Q2 2025
Sartorius Stedim Biotech has published its Q2 2025 quarterly earnings report on July 22, 2025.
Sartorius Stedim Biotech Slides: Q2 2025
Sartorius Stedim Biotech has posted slides in relation to its Q2 2025 quarterly earnings report, which was published on July 22, 2025.
Sartorius Stedim Biotech and Sensible Biotechnologies Partner to Scale Up Sensible's Unique Cell-Based mRNA Design and Manufacturing Platform
AUBAGNE, France & BRATISLAVA, Slovakia--(BUSINESS WIRE)--Sartorius Stedim Biotech and Sensible Biotechnologies are scaling up a unique cell-based manufacturing platform for clinical-grade therapeutic ...
Sartorius Stedim Biotech Earnings Call Transcript: Q1 2025
Q1 2025 saw strong growth in consumables and recurring revenue, driving margin expansion and robust cash flow, while equipment sales remained soft. Guidance for 2025 anticipates 6% sales growth and a 29%-30% EBITDA margin, with tariff impacts being actively managed.
Sartorius Stedim Biotech Earnings release: Q1 2025
Sartorius Stedim Biotech released its Q1 2025 earnings on April 16, 2025, summarizing the period's financial results.
Sartorius Stedim Biotech Slides: Q1 2025
Sartorius Stedim Biotech has posted slides in relation to its Q1 2025 quarterly earnings report, which was published on April 16, 2025.